Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway
In BRAF mutant melanoma cells, DHT suppresses the STAT3/SOX2 signaling pathway. Combining DHT, BRAF inhibitors, and MEK inhibitors can help treat treatment-resistant BRAF mutant melanoma cells. Experimental results both <i>in vitro</i> and <i>in vivo</i> have shown that the combination of DHT and an inhibitor of the MAPK pathway is safer and more successful than using an inhibitor of the MAPK pathway alone when treating BRAF mutant melanoma.
Authors
- Chuanshu Huang
- Midie Xu
- Jun Liu (ORCID: https://orcid.org/0000-0003-3671-3208)
- Yifan Liu (ORCID: https://orcid.org/0000-0002-2989-6280)
- Qiong Dai
- Yi Duan (ORCID: https://orcid.org/0000-0002-8880-2432)
- Xing Luo (ORCID: https://orcid.org/0000-0001-7358-3196)
- Zhihui Yang
- Jin‐Wei He (ORCID: https://orcid.org/0000-0001-8140-4610)
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.3389/fonc.2025.1429018
- Citations
- 3
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42